- 【Updated on January 20, 2026】 Integration of CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on November 26, 2025】Regarding the recording of “Research Data” and “Evidence Data”
- Incorporated Jxiv preprints from JaLC and adding coverage from NDL Search
Alfacalcidol Increases the Therapeutic Efficacy of Ibandronate on Bone Mineral Density in Japanese Women with Primary Osteoporosis
-
- Nakamura Yukio
- Department of Orthopaedic Surgery, Shinshu University School of Medicine Department of Orthopedic Surgery, Showa-Inan General Hospital
-
- Suzuki Takako
- Department of Orthopaedic Surgery, Shinshu University School of Medicine
-
- Kamimura Mikio
- Center of Osteoporosis and Spinal Disorders, Kamimura Orthopedic Clinic
-
- Ikegami Shota
- Department of Orthopaedic Surgery, Shinshu University School of Medicine
-
- Uchiyama Shigeharu
- Department of Orthopaedic Surgery, Shinshu University School of Medicine
-
- Kato Hiroyuki
- Department of Orthopaedic Surgery, Shinshu University School of Medicine
Bibliographic Information
- Published
- 2017
- Resource Type
- journal article
- DOI
-
- 10.1620/tjem.241.319
- Publisher
- Tohoku University Medical Press
Search this article
Description
<p>Bisphosphonates (BPs) increase bone mineral density (BMD) through the inhibition of osteoclast activity. Among BPs, ibandronate (IBN) is a strong inhibitor of bone resorption. However, the effects of a vitamin D analogue, alfacalcidol (ALF), on IBN treatment for osteoporosis is unknown. Fifty-three treatment-naïve post-menopausal women with primary osteoporosis were recruited and divided into IBN-treatment group (IBN group) and IBN with ALF group (IBN/ALF group). IBN (1.0 mg) was intravenously injected once a month, with or without oral ALF (1.0 μg/day). Ultimately, 19 subjects in IBN group and 26 in IBN/ALF group were analyzed. Bone turnover markers were examined at 4, 6, 12, and 18 months, and BMD was measured at 6, 12, and 18 months. Compared with pre-treatment, bone turnover markers significantly decreased in both groups after 4 months. The levels of serum N-terminal propeptide of type-1 procollagen and tartrate-resistant acid phosphatase-5b, and urinary N-terminal telopeptide of type-I collagen were significantly lower in IBN/ALF group than those in IBN group at 12 months. Lumbar 1-4 (L)-BMD significantly increased from 6 months in IBN/ALF group and at 18 months in IBN group. L-BMD was significantly higher in IBN/ALF group (6.6% increase) than in IBN group (3.4%) at 18 months. Total hip (H)-BMD significantly increased from 6 months in IBN/ALF group and tended to improve in IBN group. H-BMD was significantly higher in IBN/ALF group (4.8%) than in IBN group (3.2%) at 18 months. In conclusion, treatment with ALF in combination with IBN improves BMD in post-menopausal women with osteoporosis.</p>
Journal
-
- The Tohoku Journal of Experimental Medicine
-
The Tohoku Journal of Experimental Medicine 241 (4), 319-326, 2017
Tohoku University Medical Press